Aclaris makes a deal, aims to raise $80M; Emmecell’s Ph1 update in corneal edema
Plus, news about Keymed Biosciences, Ouro Medicines, Recode, Intellia, Quell, VBI Vaccines and Zai Lab:
Aclaris adds two anti-TSLP programs, seeks $80M: The new pipeline …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
